Sangamo Therapeutics to Acquire TxCell

Author's Avatar
Jul 23, 2018
Article's Main Image

The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development

Initiation of First CAR-Treg Clinical Trial Expected in 2019

PR Newswire